Simultaneous use of biologic agents in combination or with Xeljanz may be a viable treatment option for highly selected, refractory patients with inflammatory bowel disease, according to study results.
Robert Battat, MD, from the Jill Roberts Center for IBD at Weill Cornell Medicine, and colleagues wrote that many patients with IBD experience loss of response or are primary non-responders despite advances in therapies and drug optimization.
“Approximately only 40% of patients with response to biologic therapies maintain clinical remission at 1 year,” they wrote. “Drug-related adverse effects and varying treatment efficacies for extraintestinal manifestations are further obstacles to effective management.”
Researchers conducted a systematic review and meta-analysis to summarize data on the safety and effectiveness of dual biologic therapy in combination or with Xeljanz (tofacitinib, Pfizer) in patients with refractory IBD. To read the complete article, click here